Barings LLC Trims Stake in BeOne Medicines Ltd. – Sponsored ADR $ONC

Barings LLC decreased its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 23.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 42,815 shares of the company’s stock after selling 12,789 shares during the period. Barings LLC’s holdings in BeOne Medicines were worth $13,008,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Group One Trading LLC purchased a new position in BeOne Medicines in the fourth quarter valued at $61,000. Deutsche Bank AG increased its holdings in BeOne Medicines by 98.8% in the fourth quarter. Deutsche Bank AG now owns 60,656 shares of the company’s stock valued at $18,428,000 after buying an additional 30,142 shares in the last quarter. Cerity Partners LLC increased its holdings in BeOne Medicines by 174.3% in the fourth quarter. Cerity Partners LLC now owns 2,167 shares of the company’s stock valued at $658,000 after buying an additional 1,377 shares in the last quarter. LPL Financial LLC increased its holdings in BeOne Medicines by 15.0% in the fourth quarter. LPL Financial LLC now owns 4,065 shares of the company’s stock valued at $1,235,000 after buying an additional 529 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of BeOne Medicines by 125.4% in the fourth quarter. Franklin Resources Inc. now owns 94,594 shares of the company’s stock valued at $28,739,000 after buying an additional 52,627 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ONC. Leerink Partners increased their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Truist Financial reissued a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

BeOne Medicines Stock Down 1.3%

NASDAQ ONC opened at $260.27 on Friday. The business has a fifty day moving average price of $300.30 and a 200 day moving average price of $314.98. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The company has a market cap of $28.56 billion, a P/E ratio of 58.23 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. Research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other BeOne Medicines news, insider Titus B. Ball sold 136 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $271.33, for a total value of $36,900.88. Following the completion of the sale, the insider owned 36 shares in the company, valued at approximately $9,767.88. This represents a 79.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Chan Henry Lee sold 871 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $270.42, for a total value of $235,535.82. Following the completion of the sale, the senior vice president directly owned 160 shares of the company’s stock, valued at $43,267.20. This trade represents a 84.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 10,098 shares of company stock worth $2,780,482 in the last 90 days. Corporate insiders own 6.19% of the company’s stock.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.